Posted On: 07/26/2016 4:44:42 PM
Post# of 4
Biostage (Nasdaq: BSTG) is a compelling investment opportunity in regenerative medicine - they have been successful in using stem cells and a scaffold to create organ implants for tubular organs. Best success in regenerating the esophagus in a large animal study with Mayo Clinic.
Plan is to file with FDA by year end 2016 seeking OK to start human clinical trials in 2017. Have also filed for orphan designation for esophageal implant project. $18M market cap currently.
[url=htpp://www.biostage.com]Biostage Website[/url]
Plan is to file with FDA by year end 2016 seeking OK to start human clinical trials in 2017. Have also filed for orphan designation for esophageal implant project. $18M market cap currently.
[url=htpp://www.biostage.com]Biostage Website[/url]
(2)
(0)
Posts that I make on Investors Hangout reflect my own personal thinking and opinion and are neither endorsed nor approved by the subject companies, many of which may be clients or client prospects of our our NY-based investor relations consulting firm.
David Collins, Managing Director
Catalyst Global Investor Relations
www.catalyst-ir.com
dcc@catatalyst-ir.com
212 924 9800
David Collins, Managing Director
Catalyst Global Investor Relations
www.catalyst-ir.com
dcc@catatalyst-ir.com
212 924 9800
